Drugs / HerpV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01687595 | Oct 2012 → Sep 2013 | genital herpes simplex type 2 infectious disorder | Agenus Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-06-26 | Agenus Inc. | Results Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation agenusbio.com ↗
More than half of those vaccinated developed a robust anti-HSV cytotoxic T-cell immune response, and in those patients there was a statistically significant 75% reduction in viral load (P<0.001; CI: 46.2 – 88.6%). |
| 2013-11-07 | Agenus Inc. | Results Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial agenusbio.com ↗
The primary analysis, which looked at viral shedding after the initial three injections, shows that subjects who received HerpV had a statistically significant reduction in viral shedding (P=0.015; RR=0.85). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-06-26 | Agenus Inc. | Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation agenusbio.com ↗ |
| 2013-11-07 | Agenus Inc. | Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial agenusbio.com ↗ |
| 2013-02-27 | Agenus Inc. | Agenus’ HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment agenusbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HerpV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01687595 ↗ |
| Modality | Vaccine | “HerpV vaccine” NCT01687595 ↗ |
| Route | Subcutaneous | “Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1.” NCT01687595 ↗ |